The new acting director of the US Food and Drug Administration’s Office of Generic Drugs, Susan Rosencrance, spent 24 years working there, but that experience is largely outdated after only a few years at the Office of Pharmaceutical Quality, a close partner in the ANDA assessment program.
Rosencrance, who had been director of the Office of Lifecycle Drug Products in OPQ, said OGD has changed substantially, thanks to the generic drug user fee program. Her early days...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?